The Asia Pacific Infertility Drugs Market should witness market growth of 7.0% CAGR during the forecast period (2022-2028).
Women who have trouble becoming pregnant or bringing a pregnancy to term are said to have impaired fecundity, which is a syndrome associated with infertility. In the United States, 1 in 5 heterosexual women between the ages of 15 and 49 who have never given birth are unsuccessful in becoming pregnant after a year of trying (infertility). Additionally, 26% of the women in this group report having trouble becoming pregnant or bringing a pregnancy to term (impaired fecundity).
Women who have given birth one or more times before are less likely to have infertility and reduced fecundity. Approximately 6% of married women in this demographic, who are between the ages of 15 and 49, are unable to conceive after a year of trying, and 14% have trouble becoming pregnant or bringing a baby to term.
The likelihood of a woman conceiving twins, triplets, or other multiples is increased by several reproductive medications. Multiple pregnancy might cause a woman's pregnancy to be more problematic. Premature birth is more likely in situations with multiple foetuses (too early). Premature infants are more likely to have health and developmental issues. Drugs for infertility become necessary as a result.
Among women of reproductive age, Polycystic Ovarian Syndrome (PCOS) is one of the most prevalent hormonal illnesses. Women who come with infertility often have been diagnosed with PCOS. As a result of the lack of a clear definition for the illness, the actual prevalence of PCOS is unknown. Worldwide, the prevalence of PCOS ranges from 2.2% to 26%. Prevalence rates in a few Asian nations range from 2% to 7.5% in China and 6.3% in Sri Lanka. Couples have pregnancy problems as a result of the growth of these disorders. As a result, the Asia Pacific region is seeing an increase in demand for infertility medications.
The China market dominated the Asia Pacific Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $365.8 million by 2028. The Japan market is registering a CAGR of 6.3% during (2022-2028). Additionally, The India market would showcase a CAGR of 7.6% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Women who have trouble becoming pregnant or bringing a pregnancy to term are said to have impaired fecundity, which is a syndrome associated with infertility. In the United States, 1 in 5 heterosexual women between the ages of 15 and 49 who have never given birth are unsuccessful in becoming pregnant after a year of trying (infertility). Additionally, 26% of the women in this group report having trouble becoming pregnant or bringing a pregnancy to term (impaired fecundity).
Women who have given birth one or more times before are less likely to have infertility and reduced fecundity. Approximately 6% of married women in this demographic, who are between the ages of 15 and 49, are unable to conceive after a year of trying, and 14% have trouble becoming pregnant or bringing a baby to term.
The likelihood of a woman conceiving twins, triplets, or other multiples is increased by several reproductive medications. Multiple pregnancy might cause a woman's pregnancy to be more problematic. Premature birth is more likely in situations with multiple foetuses (too early). Premature infants are more likely to have health and developmental issues. Drugs for infertility become necessary as a result.
Among women of reproductive age, Polycystic Ovarian Syndrome (PCOS) is one of the most prevalent hormonal illnesses. Women who come with infertility often have been diagnosed with PCOS. As a result of the lack of a clear definition for the illness, the actual prevalence of PCOS is unknown. Worldwide, the prevalence of PCOS ranges from 2.2% to 26%. Prevalence rates in a few Asian nations range from 2% to 7.5% in China and 6.3% in Sri Lanka. Couples have pregnancy problems as a result of the growth of these disorders. As a result, the Asia Pacific region is seeing an increase in demand for infertility medications.
The China market dominated the Asia Pacific Infertility Drugs Market by Country in 2021; thereby, achieving a market value of $365.8 million by 2028. The Japan market is registering a CAGR of 6.3% during (2022-2028). Additionally, The India market would showcase a CAGR of 7.6% during (2022-2028).
Based on End-user, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Based on Drug Class, the market is segmented into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
By End-user
- Women
- Men
By Distribution Channel
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Online Pharmacy
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Infertility Drugs Market, by End User
1.4.2 Asia Pacific Infertility Drugs Market, by Distribution Channel
1.4.3 Asia Pacific Infertility Drugs Market, by Drug Class
1.4.4 Asia Pacific Infertility Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Infertility Drugs Market by End-user
3.1 Asia Pacific Women Market by Country
3.2 Asia Pacific Men Market by Country
Chapter 4. Asia Pacific Infertility Drugs Market by Distribution Channel
4.1 Asia Pacific Hospital Pharmacy Market by Country
4.2 Asia Pacific Specialty & Retail Pharmacy Market by Country
4.3 Asia Pacific Online Pharmacy Market by Country
Chapter 5. Asia Pacific Infertility Drugs Market by Drug Class
5.1 Asia Pacific Gonadotropins Market by Country
5.2 Asia Pacific Aromatase Inhibitors Market by Country
5.3 Asia Pacific Selective Estrogen Receptor Modulators (SERMs) Market by Country
5.4 Asia Pacific Dopamine Agonists Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Infertility Drugs Market by Country
6.1 China Infertility Drugs Market
6.1.1 China Infertility Drugs Market by End-user
6.1.2 China Infertility Drugs Market by Distribution Channel
6.1.3 China Infertility Drugs Market by Drug Class
6.2 Japan Infertility Drugs Market
6.2.1 Japan Infertility Drugs Market by End-user
6.2.2 Japan Infertility Drugs Market by Distribution Channel
6.2.3 Japan Infertility Drugs Market by Drug Class
6.3 India Infertility Drugs Market
6.3.1 India Infertility Drugs Market by End-user
6.3.2 India Infertility Drugs Market by Distribution Channel
6.3.3 India Infertility Drugs Market by Drug Class
6.4 South Korea Infertility Drugs Market
6.4.1 South Korea Infertility Drugs Market by End-user
6.4.2 South Korea Infertility Drugs Market by Distribution Channel
6.4.3 South Korea Infertility Drugs Market by Drug Class
6.5 Singapore Infertility Drugs Market
6.5.1 Singapore Infertility Drugs Market by End-user
6.5.2 Singapore Infertility Drugs Market by Distribution Channel
6.5.3 Singapore Infertility Drugs Market by Drug Class
6.6 Malaysia Infertility Drugs Market
6.6.1 Malaysia Infertility Drugs Market by End-user
6.6.2 Malaysia Infertility Drugs Market by Distribution Channel
6.6.3 Malaysia Infertility Drugs Market by Drug Class
6.7 Rest of Asia Pacific Infertility Drugs Market
6.7.1 Rest of Asia Pacific Infertility Drugs Market by End-user
6.7.2 Rest of Asia Pacific Infertility Drugs Market by Distribution Channel
6.7.3 Rest of Asia Pacific Infertility Drugs Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Bayer AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Acquisition and Mergers:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Merck & Co., Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Ferring Holdings SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research and Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Organon & Co.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Mankind Pharma Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Product Launches and Product Expansions:
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Methodology
LOADING...
